[Tremelimumab and durvalumab (NSCLC) - Addendum to Commissions A23-29 and A23-31]

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018005250
German
Original Title: Tremelimumab und Durvalumab (NSCLC) - Addendum zum Projekt A23-29 | A23-31
Details
Project Status: Completed
Year Published: 2023
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Antineoplastic Agents, Immunological
Keywords
  • Durvalumab
  • Tremelimumab
  • Carcinoma – Non-Small-Cell Lung
  • Benefit Assessment
  • NCT03164616
  • NCT02142738
  • NCT02220894
  • NCT03215706
Contact
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: <p>Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.